Neurology
Natalizumab and your FAA medical
Selective adhesion-molecule inhibitor, biologic
Other names: Tysabri
Wait
2 weeks
ground trial when starting
Different waits apply in other cases.
FAA label
CONDITIONALLY ACCEPTABLE
The FAA lists natalizumab as conditionally acceptable, depending on the underlying condition, with a two-week ground trial when starting and 48 hours of no-fly after each dose, under its REMS program.
Track your medicationsMore detail: natalizumabThe rest of Crosscheck's reading, in plain wordsOpen
Wait
- 48 hours no-fly after each dose
- a forty-eight hour ground trial when changing from one biologic or biosimilar to another for the same indication
Changing from one biologic or biosimilar to another for the same indication requires a 48-hour ground trial.
- 14 days after starting: ground observation
- 48 hours after each dose: no flying
Show the FAA's words: natalizumabThe official FAA wording: two passages, each with its document and dateOpen
Initial observation: All require a 2-week no-fly/ground trial to verify no side effects.
CONDITIONALLY ACCEPTABLE BIOLOGIC MEDICATIONS Monotherapy — Dependent on underlying condition(s), see those pages.
Selective Adhesion-Molecule Inhibitor: natalizumab (Tysabri), REMS program (due to the risk of progressive multifocal leukoencephalopathy [PML]), 48 hours
Changing from one biologic/biosimilar to another for the same indication requires a forty-eight (48) hour ground trial to mitigate any aeromedical risk.